Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer

Figure 2

Kaplan-Meier survival curves of (A) disease-free survival and (B) overall survival between treatment groups. HR, hazard ratio; CI, confidence interval; (--), weekly docetaxel; (---), 3-weekly docetaxel

Back to article page